These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 26190401)

  • 1. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
    Peng C; Gathagan RJ; Lee VM
    Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
    Cascella R; Bigi A; Cremades N; Cecchi C
    Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation.
    Rokad D; Ghaisas S; Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Brain Res Bull; 2017 Jul; 133():60-70. PubMed ID: 27993598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein misfolding and neurodegenerative diseases.
    Uversky VN
    Curr Protein Pept Sci; 2008 Oct; 9(5):507-40. PubMed ID: 18855701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease.
    Gonçalves SA; Outeiro TF
    Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein.
    Ahsan N; Mishra S; Jain MK; Surolia A; Gupta S
    Sci Rep; 2015 May; 5():9862. PubMed ID: 25985292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seeking a mechanism for the toxicity of oligomeric α-synuclein.
    Roberts HL; Brown DR
    Biomolecules; 2015 Mar; 5(2):282-305. PubMed ID: 25816357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies.
    Sampaio-Marques B; Ludovico P
    Biomolecules; 2015 May; 5(2):735-57. PubMed ID: 25946078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
    Paleologou KE; Irvine GB; El-Agnaf OM
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein aggregation mechanisms in synucleinopathies: commonalities and differences.
    Beyer K; Ariza A
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):965-74. PubMed ID: 17984679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular models of alpha-synuclein toxicity and aggregation.
    Delenclos M; Burgess JD; Lamprokostopoulou A; Outeiro TF; Vekrellis K; McLean PJ
    J Neurochem; 2019 Sep; 150(5):566-576. PubMed ID: 31265132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.
    Vicente Miranda H; Szego ÉM; Oliveira LMA; Breda C; Darendelioglu E; de Oliveira RM; Ferreira DG; Gomes MA; Rott R; Oliveira M; Munari F; Enguita FJ; Simões T; Rodrigues EF; Heinrich M; Martins IC; Zamolo I; Riess O; Cordeiro C; Ponces-Freire A; Lashuel HA; Santos NC; Lopes LV; Xiang W; Jovin TM; Penque D; Engelender S; Zweckstetter M; Klucken J; Giorgini F; Quintas A; Outeiro TF
    Brain; 2017 May; 140(5):1399-1419. PubMed ID: 28398476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
    Alam P; Bousset L; Melki R; Otzen DE
    J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A glimpse into the structural properties of α-synuclein oligomers.
    Santos J; Pallarès I; Ventura S
    Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
    Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
    J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.